Published in PLoS One on September 14, 2010
In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment. Health Aff (Millwood) (2012) 1.84
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A (2012) 1.54
HIV treatment produces economic returns through increased work and education, and warrants continued US support. Health Aff (Millwood) (2012) 1.00
CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda. AIDS (2014) 0.89
Effect of antiretroviral therapy on patients' economic well being: five-year follow-up. AIDS (2014) 0.87
Massive benefits of antiretroviral therapy in Africa. J Infect Dis (2013) 0.82
The Impact of ART on the Economic Outcomes of People Living with HIV/AIDS. AIDS Res Treat (2013) 0.81
Prospective cohort study of the impact of antiretroviral therapy on employment outcomes among HIV clients in Uganda. AIDS Patient Care STDS (2013) 0.79
Medical pluralism predicts non-ART use among parents in need of ART: a community survey in KwaZulu-Natal, South Africa. AIDS Behav (2015) 0.78
Impact of HIV on and the constructions of masculinities among HIV-positive men in South Africa: implications for secondary prevention programs. Glob Health Action (2014) 0.77
Health Shocks and Natural Resource Management: Evidence from Western Kenya. J Environ Econ Manage (2015) 0.77
Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. BMC Infect Dis (2016) 0.75
"Times Are Changing": The Impact of HIV Diagnosis on Sub-Saharan Migrants' Lives in France. PLoS One (2017) 0.75
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS (2006) 6.46
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS (2008) 3.71
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care (2009) 2.11
An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care (2005) 1.87
Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. AIDS Care (2007) 1.80
Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J (2007) 1.77
Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic) (2008) 1.31
Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya. AIDS Care (2010) 1.03
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Improved diagnostic testing and malaria treatment practices in Zambia. JAMA (2007) 7.15
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health (2010) 3.79
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA (2008) 3.78
Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health (2010) 3.34
The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health (2008) 3.16
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One (2012) 2.88
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med (2011) 2.76
Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ (2010) 2.68
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn (2010) 2.47
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr (2012) 2.41
Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med (2011) 2.23
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol (2012) 2.19
Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health (2010) 2.05
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS (2010) 1.92
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis (2006) 1.87
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 1.86
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J (2007) 1.77
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2013) 1.77
Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat (2010) 1.75
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One (2013) 1.71
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med (2005) 1.67
How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS One (2012) 1.66
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr (2008) 1.62
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health (2013) 1.58
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J (2012) 1.58
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health (2012) 1.57
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS (2009) 1.56
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom (2008) 1.50
Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa. Lancet (2005) 1.45
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc (2010) 1.45
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis (2006) 1.44
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr (2011) 1.42
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis (2003) 1.41
Dr. Timothy Miller: A career in service to military, patients, veterans. Bull Am Coll Surg (2015) 1.39
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health (2014) 1.38
Defining retention and attrition in pre-antiretroviral HIV care: proposals based on experience in Africa. Trop Med Int Health (2012) 1.37
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis (2011) 1.33
Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic) (2008) 1.31
The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J (2008) 1.30
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis (2009) 1.30
Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health (2012) 1.29
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS (2003) 1.29
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS (2011) 1.28
Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS (2013) 1.20
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol (2009) 1.20
Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health (2010) 1.18
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis (2008) 1.17
Implementation of a safer conception service for HIV-affected couples in South Africa. AIDS (2014) 1.17
Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. PLoS One (2013) 1.16
Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough. AIDS Res Treat (2013) 1.14
Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One (2011) 1.14
Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS (2013) 1.12
Treatment outcomes after 7 years of public-sector HIV treatment. AIDS (2012) 1.11
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis (2012) 1.11
The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc (2011) 1.11
The cost of HIV/AIDS to businesses in southern Africa. AIDS (2004) 1.08
Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. AIDS Educ Prev (2009) 1.07
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis (2010) 1.07
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med (2014) 1.06
Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy. PLoS One (2013) 1.05
CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom (2008) 1.03